Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2-3
|
| pubmed:dateCreated |
1993-2-25
|
| pubmed:abstractText |
Ten multiple sclerosis patients, all with a rapid deteriorating disease profile, were treated with 12 mg/m2 of the cytostatic agent mitoxantrone, administered every 3 months. This dosage is only 25% of what a patient with a solid tumour would normally receive during the same time period. In all treated patients the deterioration was stopped following the initial dosage; in four out of ten patients there was even an immediate improvement of the neurological status. Eight out of nine patients showed an improvement after 1 year as compared with their enrollment status; the other one remained stabile. In correlation with the clinical improvement, the mean P100 latencies of visual evoked potentials showed a reduction after 1 year. However, the changes identified through magnetic resonance imaging were even clearer than those seen clinically. At admission, this group of patients presented with a total of 169 gadolinium (Gd)-enhancing lesions. Only 10 lesions were enhancing in nine patients 12 months after the initiation of treatment. It appears that mitoxantrone accelerates the disappearance of Gd-enhancing lesions and prevents the development of new ones. Minimal side effects such as mild nausea and a slight faintness were evident in six patients and then for only 1-2 days.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0940-1334
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
242
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
96-102
|
| pubmed:dateRevised |
2009-5-11
|
| pubmed:meshHeading |
pubmed-meshheading:1486115-Adult,
pubmed-meshheading:1486115-Brain,
pubmed-meshheading:1486115-Evoked Potentials, Visual,
pubmed-meshheading:1486115-Female,
pubmed-meshheading:1486115-Humans,
pubmed-meshheading:1486115-Immunosuppression,
pubmed-meshheading:1486115-Infusions, Intravenous,
pubmed-meshheading:1486115-Leukocytes,
pubmed-meshheading:1486115-Magnetic Resonance Imaging,
pubmed-meshheading:1486115-Male,
pubmed-meshheading:1486115-Middle Aged,
pubmed-meshheading:1486115-Mitoxantrone,
pubmed-meshheading:1486115-Multiple Sclerosis,
pubmed-meshheading:1486115-Neurologic Examination,
pubmed-meshheading:1486115-Pilot Projects,
pubmed-meshheading:1486115-Treatment Outcome
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Treatment of multiple sclerosis with mitoxantrone.
|
| pubmed:affiliation |
Department of Neurology, Ulm University, Dietenbronn/Schwend, Federal Republic of Germany.
|
| pubmed:publicationType |
Journal Article
|